Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Appropriations For CDER, CBER Would Grow In FY 2012 Under House Bill That Keeps FDA Flat

This article was originally published in The Pink Sheet Daily

Executive Summary

Funding bill prepared for mark-up on May 24 relies on growth in user fees and reductions elsewhere in the FDA budget.

You may also be interested in...



House Approps Bill Would "Harden" Science Requirements For FDA Rules, Guidance

Provision meant to protect ranchers/farmers could unleash Pandora's box of impediments to regulations, guidance; panel debates Avastin.

House Approps Bill Would "Harden" Science Requirements For FDA Rules, Guidance

Provision meant to protect ranchers/farmers could unleash Pandora's box of impediments to regulations, guidance; panel debates Avastin.

FDA Budget To Rise By $418 Million In FY 11 As Congress Decides To Cut Spending Elsewhere

The agency budget reflects the federal government's responsibility for public health and safety, Senate Appropriations Committee explains.

Related Content

Topics

UsernamePublicRestriction

Register

PS072275

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel